# US 12,005,172 B2 · Compositions and methods for plasmapheresis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,005,172 B2 - Document ID: US12005172B2 - Status: Granted - Kind: B2 - Application number: 18/204,293 - Filed: 2023-05-31 - Published: 2023-11-30 - Granted: 2024-06-11 - Earliest claimed: 2022-05-31 - Assignees: Lyfspn, Inc. - Applicants: Lyfspn, Inc. - Inventors: Dobri Kiprov - Web page: https://patentgrep.com/patent/US12005172B2 ## CPC - G01N 33/56972: {White blood cells} - A61B 5/0022: {Monitoring a patient using a global network, e.g. telephone networks, internet} - A61B 5/1118: {Determining activity level} - A61B 5/1122: {of movement trajectories} - A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51) - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61M 1/342: {Adding solutions to the blood, e.g. substitution solutions (for preventing coagulation A61M1/3672)} - A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)} - A61M 1/36: Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation {; Extra-corporeal blood circuits} - A61M 1/361: {before treatment} - A61M 1/3612: {after treatment} - A61M 1/38: Removing constituents from donor blood and {storing or} returning remainder to body {, e.g. for transfusion} - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61B 5/1114: {Tracking parts of the body} - A61M 1/362: {changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity} - A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging} - G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 - G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 - G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging. ## Claims ### Claim 1 A method of providing plasmapheresis to an individual in order to improve a health status of the individual, comprising the steps of: (a) measuring, before an administration of plasmapheresis, one or more of a strength of the individual, a balance of the individual, a mental status of the individual, and a walking of the individual, thereby generating a pre-treatment health status of the individual; (b) administering plasmapheresis to the individual; (c) measuring, following step (b), one or more of the strength of the individual, the balance of the individual, the mental status of the individual, and the walking of the individual, thereby generating a post-treatment health status of the individual; (d) comparing the post-treatment health status of the individual with the pre-treatment health status of the individual, wherein the comparing the post-treatment health status of the individual with the pre-treatment health status of the individual results in a determination of a quantitative difference between the post-treatment health status of the individual and the pre-treatment health status of the individual; and (e) repeating steps (b) through (d) until the quantitative difference between the post-treatment health status of the individual and the pre-treatment health status of the individual is a specific value. ### Claim 2 (depends on 1) The method of claim 1, wherein step (a) occurs within 24 hours of the administering of the plasmapheresis to the individual in step (b). ### Claim 3 (depends on 1) The method of claim 1, wherein the strength of the individual is measured in step (a), step (c), or steps (a) and (c) by measuring a grip strength of the individual. ### Claim 4 (depends on 1) The method of claim 1, wherein the balance of the individual is measured in step (a), step (c), or steps (a) and (c) by having the individual stand on one leg and measuring how long the individual remains standing with one leg raised. ### Claim 5 (depends on 1) The method of claim 1, wherein the mental status is measured in step (a), step (c), or steps (a) and (c) using a survey comprising questions that assess emotional wellbeing. ### Claim 6 (depends on 1) The method of claim 1, wherein the walking of the individual is measured in step (a), step (c), or steps (a) and (c) by having the individual stand from a seated position and walk. ### Claim 7 (depends on 1) The method of claim 1, wherein the plasmapheresis that is administered in step (b) exchanges at least one unit of plasma volume. ### Claim 8 (depends on 1) The method of claim 1, wherein the plasmapheresis that is administered in step (b) is administered over a plurality of treatment sessions. ### Claim 9 (depends on 8) The method of claim 8, wherein two treatment sessions of the plurality of treatment sessions are within 72 hours of each other. ### Claim 10 (depends on 1) The method of claim 1, wherein the plasmapheresis that is administered in step (b) is administered over a single treatment session. ### Claim 11 (depends on 1) The method of claim 1, comprising repeating step (a) before repeating steps (b) through (d). ### Claim 12 A method of providing plasmapheresis to an individual in order to improve a health status of the individual, comprising the steps of: (a) measuring, before an administration of plasmapheresis, one or more of a strength of the individual, a balance of the individual, a mental status of the individual, and a walking of the individual, thereby generating a pre-treatment health status of the individual; (b) administering plasmapheresis to the individual; (c) measuring, following step (b), one or more of the strength of the individual, the balance of the individual, the mental status of the individual, and the walking of the individual, thereby generating a post-treatment health status of the individual; (d) comparing the post-treatment health status of the individual with the pre-treatment health status of the individual, wherein the comparing the post-treatment health status of the individual with the pre-treatment health status of the individual results in a determination of a quantitative difference between the post-treatment health status of the individual and the pre-treatment health status of the individual; and (e) repeating steps (b) and (c) until the post-treatment health status of the individual is a specific value.